PL192560B1 - Sposób zmniejszania wielkości mikrocząstek i kompozycja zawierająca mikrocząstki - Google Patents

Sposób zmniejszania wielkości mikrocząstek i kompozycja zawierająca mikrocząstki

Info

Publication number
PL192560B1
PL192560B1 PL331715A PL33171597A PL192560B1 PL 192560 B1 PL192560 B1 PL 192560B1 PL 331715 A PL331715 A PL 331715A PL 33171597 A PL33171597 A PL 33171597A PL 192560 B1 PL192560 B1 PL 192560B1
Authority
PL
Poland
Prior art keywords
water
surfactant
particle size
microparticles
insoluble
Prior art date
Application number
PL331715A
Other languages
English (en)
Polish (pl)
Other versions
PL331715A1 (en
Inventor
Indu Parikh
Ulagaraj Selvaraj
Original Assignee
Res Triangle Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Pharm Ltd filed Critical Res Triangle Pharm Ltd
Publication of PL331715A1 publication Critical patent/PL331715A1/xx
Publication of PL192560B1 publication Critical patent/PL192560B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/827—Nanostructure formed from hybrid organic/inorganic semiconductor compositions
    • Y10S977/828—Biological composition interconnected with inorganic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/882—Assembling of separate components, e.g. by attaching
    • Y10S977/883—Fluidic self-assembly, FSA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/931—Medical device coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL331715A 1996-08-22 1997-03-28 Sposób zmniejszania wielkości mikrocząstek i kompozycja zawierająca mikrocząstki PL192560B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70148396A 1996-08-22 1996-08-22
PCT/US1997/004695 WO1998007414A1 (en) 1996-08-22 1997-03-28 Compositions comprising microparticles of water-insoluble substances and method for preparing same

Publications (2)

Publication Number Publication Date
PL331715A1 PL331715A1 (en) 1999-08-02
PL192560B1 true PL192560B1 (pl) 2006-11-30

Family

ID=24817566

Family Applications (1)

Application Number Title Priority Date Filing Date
PL331715A PL192560B1 (pl) 1996-08-22 1997-03-28 Sposób zmniejszania wielkości mikrocząstek i kompozycja zawierająca mikrocząstki

Country Status (19)

Country Link
US (2) US5922355A (enExample)
EP (1) EP0925061B1 (enExample)
JP (1) JP2000516244A (enExample)
KR (1) KR100542816B1 (enExample)
CN (1) CN1303985C (enExample)
AT (1) ATE314055T1 (enExample)
AU (1) AU719085B2 (enExample)
CA (1) CA2263102C (enExample)
CZ (1) CZ299790B6 (enExample)
DE (1) DE69734988T2 (enExample)
ES (1) ES2252780T3 (enExample)
HU (1) HU226608B1 (enExample)
IL (1) IL128632A (enExample)
NO (1) NO325197B1 (enExample)
NZ (1) NZ333844A (enExample)
PL (1) PL192560B1 (enExample)
RO (1) RO120603B1 (enExample)
RU (1) RU2186562C2 (enExample)
WO (1) WO1998007414A1 (enExample)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633222T2 (de) * 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
JP5038552B2 (ja) 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1067914B1 (en) 1998-03-30 2006-02-22 Jagotec Ag Composition and method of preparing microparticles of water-insoluble substances
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1160059C (zh) 1998-06-19 2004-08-04 斯凯伊药品加拿大公司 生产水不溶性化合物的亚微粒子的方法
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
HUP0105089A3 (en) * 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
KR20010075713A (ko) * 1998-11-20 2001-08-09 추후제출 불용성 마이크로입자의 안정된 현탁액의 제조방법
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
ES2469642T3 (es) 2000-04-20 2014-06-18 Jagotec Ag Procedimiento mejorado para partículas de fármaco insoluble en agua
DE60133270T2 (de) 2000-05-10 2009-04-23 Jagotec Ag Zerkleinerung mittels mahlkörper
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002017883A2 (en) 2000-08-31 2002-03-07 Rtp Pharma Inc. Milled particles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
EP1320362B1 (en) * 2000-09-20 2011-08-31 Jagotec AG Stabilised fibrate microparticles
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
JP4541647B2 (ja) * 2000-11-20 2010-09-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
EA200301223A1 (ru) * 2001-05-18 2004-08-26 Рэнбакси Лабораториз Лимитед Лекарственные формы окскарбазепина
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2002336867A1 (en) * 2001-11-02 2003-05-12 Qlt Inc. Micelle compositions containing pegylated phospholipids and a photosensitizer
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2003066021A2 (en) 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20060280761A1 (en) * 2002-03-11 2006-12-14 Health Plus International, Inc. Nanofluidized B-12 composition and process for treating pernicious anemia
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
JP4842514B2 (ja) * 2002-03-20 2011-12-21 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003088951A1 (en) * 2002-04-15 2003-10-30 Eiffel Technologies Limited Formulation of fine particles using liquefied or dense gases
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
EP1549293A1 (en) * 2002-09-16 2005-07-06 Vasogen Ireland Limited Accelerating recovery from trauma
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
EP2557788A1 (en) * 2002-11-29 2013-02-13 Sony Corporation Encoding apparatus and the method
JPWO2004052354A1 (ja) * 2002-12-06 2006-04-06 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
JP2004323444A (ja) * 2003-04-25 2004-11-18 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 凍結乾燥微粒子製剤およびその製法
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
ATE383859T1 (de) * 2004-01-08 2008-02-15 Wyeth Corp Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
AU2005206163B2 (en) * 2004-01-14 2011-06-30 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
WO2006026592A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
ATE454134T1 (de) * 2005-04-13 2010-01-15 Abbott Gmbh & Co Kg Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US7810743B2 (en) 2006-01-23 2010-10-12 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid delivery device
US7703698B2 (en) * 2006-09-08 2010-04-27 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment chamber and continuous flow mixing system
KR100919731B1 (ko) * 2006-05-11 2009-09-29 재단법인서울대학교산학협력재단 안정제로서 폴리에테르를 함유한 백신전달용 키토산미립자
US9283188B2 (en) * 2006-09-08 2016-03-15 Kimberly-Clark Worldwide, Inc. Delivery systems for delivering functional compounds to substrates and processes of using the same
US8034286B2 (en) * 2006-09-08 2011-10-11 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment system for separating compounds from aqueous effluent
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US7712353B2 (en) 2006-12-28 2010-05-11 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment system
US7673516B2 (en) * 2006-12-28 2010-03-09 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment system
CN101677954A (zh) 2007-02-11 2010-03-24 Map药物公司 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
CN101610754A (zh) 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US7998322B2 (en) * 2007-07-12 2011-08-16 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber having electrode properties
US7785674B2 (en) * 2007-07-12 2010-08-31 Kimberly-Clark Worldwide, Inc. Delivery systems for delivering functional compounds to substrates and processes of using the same
US7947184B2 (en) * 2007-07-12 2011-05-24 Kimberly-Clark Worldwide, Inc. Treatment chamber for separating compounds from aqueous effluent
US8858892B2 (en) 2007-12-21 2014-10-14 Kimberly-Clark Worldwide, Inc. Liquid treatment system
US8454889B2 (en) 2007-12-21 2013-06-04 Kimberly-Clark Worldwide, Inc. Gas treatment system
US8632613B2 (en) 2007-12-27 2014-01-21 Kimberly-Clark Worldwide, Inc. Process for applying one or more treatment agents to a textile web
US20090166177A1 (en) 2007-12-28 2009-07-02 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing emulsions
US8206024B2 (en) 2007-12-28 2012-06-26 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for particle dispersion into formulations
US8057573B2 (en) 2007-12-28 2011-11-15 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for increasing the shelf life of formulations
US8215822B2 (en) * 2007-12-28 2012-07-10 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing antimicrobial formulations
US9421504B2 (en) 2007-12-28 2016-08-23 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing emulsions
GB0803969D0 (en) * 2008-03-04 2008-04-09 Britannia Pharmaceuticals Ltd Improved phospholipid and method for its production
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
EP2334845A2 (en) * 2008-10-06 2011-06-22 Katholieke Universiteit Leuven K.U. Leuven R&D Functional layers of biomolecules and living cells, and a novel system to produce such
US8685178B2 (en) 2008-12-15 2014-04-01 Kimberly-Clark Worldwide, Inc. Methods of preparing metal-modified silica nanoparticles
US8163388B2 (en) 2008-12-15 2012-04-24 Kimberly-Clark Worldwide, Inc. Compositions comprising metal-modified silica nanoparticles
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
IT1398857B1 (it) 2009-06-10 2013-03-21 Univ Padova Coniugati polimerici fosfolipidi
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
WO2011059931A2 (en) * 2009-11-10 2011-05-19 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
CN102652015B (zh) 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物
ES2524402T3 (es) * 2010-04-16 2014-12-09 San-Ei Gen F.F.I., Inc. Procedimiento para enmascarar el sabor de la curcumina
US9492387B2 (en) 2010-10-29 2016-11-15 Western University Of Health Sciences Ternary mixture formulations
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
RS65237B1 (sr) 2011-03-18 2024-03-29 Alkermes Pharma Ireland Ltd Farmaceutske kompozicije koje sadrže sorbitan estre
WO2013066735A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Nano-suspension process
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JP6219918B2 (ja) * 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
NZ748572A (en) 2012-09-19 2020-07-31 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
EP3067462B1 (en) * 2013-11-07 2018-08-22 Unicharm Corporation Composite material for absorbent article, and method for manufacturing said material
JP6524110B2 (ja) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
RU2737893C2 (ru) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
US20170320862A1 (en) * 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CN107875436B (zh) * 2017-11-10 2020-02-18 杭州华微医疗科技有限公司 一种负载碳酸氢钠粉末的液体栓塞剂组合物及其应用
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
EP4056038A1 (en) * 2021-03-10 2022-09-14 Basf Se Microparticles containing active substances

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56152739A (en) * 1980-04-25 1981-11-26 Tanabe Seiyaku Co Ltd Production of microcapsule
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
FR2617047B1 (fr) 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
DE68900991D1 (de) 1988-01-29 1992-04-23 Sankyo Co Cyclosporin-zusammensetzungen.
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2013755C (en) * 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE59310166D1 (de) 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
CA2091152C (en) * 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
US5364633A (en) * 1994-03-14 1994-11-15 Dow Corning Corporation Silicone vesicles and entrapment
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
JP5038552B2 (ja) * 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達

Also Published As

Publication number Publication date
US5922355A (en) 1999-07-13
NZ333844A (en) 2000-10-27
CA2263102A1 (en) 1998-02-26
KR100542816B1 (ko) 2006-01-11
CN1303985C (zh) 2007-03-14
CA2263102C (en) 2006-08-15
EP0925061A1 (en) 1999-06-30
AU719085B2 (en) 2000-05-04
RU2186562C2 (ru) 2002-08-10
HUP9903537A2 (hu) 2000-02-28
HU226608B1 (hu) 2009-04-28
WO1998007414A1 (en) 1998-02-26
JP2000516244A (ja) 2000-12-05
CN1228021A (zh) 1999-09-08
CZ299790B6 (cs) 2008-11-26
IL128632A0 (en) 2000-01-31
PL331715A1 (en) 1999-08-02
IL128632A (en) 2003-03-12
NO325197B1 (no) 2008-02-18
AU2587197A (en) 1998-03-06
HUP9903537A3 (en) 2000-05-29
RO120603B1 (ro) 2006-05-30
HK1021140A1 (en) 2000-06-02
NO990790D0 (no) 1999-02-19
ES2252780T3 (es) 2006-05-16
ATE314055T1 (de) 2006-01-15
EP0925061B1 (en) 2005-12-28
DE69734988T2 (de) 2006-09-21
US6228399B1 (en) 2001-05-08
DE69734988D1 (de) 2006-02-02
CZ59699A3 (cs) 1999-06-16
NO990790L (no) 1999-04-19
KR20000035808A (ko) 2000-06-26

Similar Documents

Publication Publication Date Title
PL192560B1 (pl) Sposób zmniejszania wielkości mikrocząstek i kompozycja zawierająca mikrocząstki
US6387409B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US6337092B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US8206746B2 (en) Microparticles of water-insoluble substances
CA2349203C (en) Dispersible phospholipid stabilized microparticles
EP1079808B1 (en) Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
AU743917B2 (en) Compositions comprising microparticles of water-insoluble substances
MXPA99001691A (es) Composiciones que comprenden microparticulas de sustancias insolubles en agua, y metodo para su preparacion